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Abstract
 
Interleukin (IL)-18 was originally regarded to induce T helper cell (Th)1-related cytokines. In
general, factors favoring interferon (IFN)-
 
  
 
production are believed to abolish allergic diseases.
Thus, we tested the role of IL-18 in regulation of bronchial asthma. To avoid a background
response of host-derived T cells, we administered memory type Th1 or Th2 cells into unsensi-
tized mice and examined their role in induction of bronchial asthma. Administration of antigen
(Ag) induced both airway inflammation and airway hyperresponsiveness (AHR) in mice receiving
memory Th2 cells. In contrast, the same treatment induced only airway inflammation but not
AHR in mice receiving memory Th1 cells. However, these mice developed striking AHR
 
when they were coadministered with IL-18. Furthermore, mice having received IFN-
 
 
 
–
expressing Th1 cells sorted from polarized Th1 cells developed severe airway inflammation and
AHR after intranasal administration of Ag and IL-18. Thus, Th1 cells become harmful when
they are stimulated with Ag and IL-18. Newly polarized Th1 cells and IFN-
 
 
 
–expressing Th1
cells, both of which express IL-18 receptor 
 
  
 
chain strongly, produce IFN-
 
 
 
, IL-9, IL-13,
granulocyte/macrophage colony-stimulating factor, tumor necrosis factor 
 
 
 
, regulated on acti-
vation, normal T cell expressed and secreted, and macrophage inflammatory protein 1
 
  
 
upon
stimulation with Ag, IL-2, and IL-18 in vitro. Thus, Ag and IL-18 stimulate memory Th1 cells
to induce severe airway inflammation and AHR in the naive host.
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Introduction
 
Asthma is a disease of respiratory tract caused by repeated
immediate hypersensitivity and late phase reactions in the
lungs that lead to intermittent and reversible airway obstruc-
tion (1–4). There are infiltrates of neutrophils, eosinophils,
degranulated mast cells, subbasement membrane thickening,
and hyperplasia of goblet cells in the airway. It is widely
accepted that the Th2 cytokines (IL-4, IL-5, IL-9, and IL-13)
and GM-CSF are principally responsible for inducing bron-
chial asthma (5–7). IL-4 is pivotal as the driving cytokine
toward Th2 phenotype and induces IgE production from B
cells (8). IL-5 induces maturation and activation of eosino-
phils (9). IL-4 and IL-9 are potent mast cell growth factors
(10, 11). IL-9 and IL-13 induce mucus production by causing
goblet cell hyperplasia (12–15). Furthermore, IL-13 is shown
to be necessary and sufficient to induce airway hyperrespon-
siveness (AHR; 16–19). GM-CSF induces Th2 differentiation
independently of IL-4 and also maintains the survival of
eosinophils (20). In contrast, Th1 cells had been regarded
to protect against bronchial asthma by damping the activity
of Th2 cells (21–23). However, several studies indicated
the failure of Th1 cells to attenuate Th2 cell–induced airway
hypersensitivity (1, 24–28). Furthermore, Th1 cells are re-
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ported to induce AHR by recruitment and activation of
neutrophils (29). These results prompted us to examine the
pathological relevance of passively transferred memory-
type Th1 cells in induction of bronchial asthma in unsensi-
tized host mice. Importantly, this type of study allowed us
to depict selectively the response of memory-type T cells in
the naive animals.
IL-18 was originally identified as a factor that enhances
IFN-
 
  
 
production from Th1 cells in the presence of anti-
CD3 and IL-12 (30–32). However, our recent studies and
those of others demonstrated that IL-18 promotes Th2 cy-
tokine production from T cells, NK cells, basophils, and
mast cells (33–38). As IL-18 is abundantly stored in the epi-
thelial cells of various organs (39–42), we could assume the
possibility that some types of infectious agents might stimu-
late bronchial epithelial cells to produce IL-18. Thus, it is
very important to determine the biological relevance of IL-
18 in bronchial asthma. IL-18 responsiveness is determined
by the expression of IL-18R, a heterodimeric complex
consisting of ligand-binding 
 
  
 
chain (IL-18R
 
 
 
) and an as-
sociating 
 
  
 
chain (IL-18R
 
 
 
; 38). Naive T cells, when stim-
ulated with Ag and IL-12 or IL-4, develop into Th1 or
Th2 cells, respectively (43). As IL-12 induces but IL-4
down-regulates IL-18R
 
  
 
on T cells (44, 45), only Th1 cells
become the major target cells for IL-18 and produce IFN-
 
 
 
strongly when stimulated with Ag and IL-18. However, we
recently found and reported that NKT cells constitutively
express high levels of IL-18R
 
  
 
and produce Th2 cytokines
(e.g., IL-4, IL-9, IL-13, etc.), when they are stimulated
with IL-2 and IL-18 without TCR engagement, although
they have the potential to produce a large amount of IFN-
 
 
 
in response to IL-12 and IL-18 (35). Therefore, it is impor-
tant to investigate whether IL-18R
 
 
 
–expressing Th1 cells
also have the potential to produce Th1 or Th2 cytokines in
response to IL-18 depending on cytokine milieu.
Here we have demonstrated that adoptively transferred
memory-type Th1 cells when stimulated with Ag in the
lung induce airway inflammation without AHR. In con-
trast, memory Th1 cells induce both severe airway inflam-
mation and AHR when they are stimulated with Ag and
IL-18. Surprisingly, like activated mast cells, Ag plus IL-
18–stimulated Th1 cells produce IFN-
 
 
 
, IL-9, IL-13, GM-
CSF, TNF-
 
 
 
, regulated on activation, normal T cell
expressed and secreted (RANTES), and macrophage in-
flammatory protein (MIP)-1
 
 
 
, suggesting their relevant
role in induction of bronchial asthma.
 
Materials and Methods
 
Animals and Reagents.
 
Specific pathogen-free female BALB/c
mice were purchased from The Jackson Laboratory. Mice trans-
genic (Tg) for 
 
   
 
TCR recognizing OVA
 
323–339 
 
(DO11.10,
BALB/c genetic background; reference 46) were provided by D.
Loh (Washington University, St. Louis, MO). All experiments
were performed on the line heterozygous for the transgene. All
mice were bred under specific pathogen-free conditions at the
animal facilities of Hyogo College of Medicine and were used at
6–10 wk of age. Recombinant mouse IL-4, obtained from a re-
 
combinant baculovirus (AcMNPV.IL-4), was purified by affinity
chromatography and used. Recombinant mouse IL-12, IL-18,
and anti–mouse IL-18R
 
  
 
chain mAb (Y38; reference 47) were
provided by Hayashibara Biochemical Laboratories Inc. PE-KJ1-
26, which recognizes TCR from DO11.10 mice, was purchased
from CALTAG Laboratories and used to specifically stain the
adoptively transferred DO11.10 TCR Tg cells. Purified antibod-
ies (anti–mouse CD28 [37.51], anti–mouse CD3 [2C11], anti–
mouse IL-4 [11B11], anti–mouse IL-12p40 [C17.8], and anti–
mouse IFN-
 
  
 
[XMG1.2]) were prepared in our laboratory. PE
anti–mouse CD4 (GK1.5) allophycocyanin (APC) anti–mouse
CD4, FITC anti–rat IgG1 (RG11/39.4), and FITC anti–mouse
IFN-
 
  
 
(XMG1.2) were purchased from BD Biosciences.
 
Generation of Th1 or Th2 Cells and Isolation of IFN-
 
 
 
  
 
Cells.
 
10
 
5
 
/ml naive splenic CD4
 
  
 
CD62L
 
  
 
T cells from DO11.10 Tg
mice were stimulated with 100 pM IL-2 and 1 
 
 
 
M OVA
 
323–339 
 
in
the presence of 10
 
6
 
/ml Ag-presenting cells (irradiated T cell–
depleted BALB/c splenocytes) in six-well plates in a total 3-ml
volume of RPMI 1640 supplemented with 10% FBS, 50 
 
 
 
M 2-ME,
2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 100 
 
 
 
g/ml strepto-
mycin for 7 d. For induction of Th1 cells, 10 ng/ml IL-12 and 10
 
 
 
g/ml anti–IL-4 (11B11) were further added to the culture. For
induction of Th2 cells, 1,000 U/ml IL-4, 10 
 
 
 
g/ml anti–IL-
12p40, and 10 
 
 
 
g/ml anti–IFN-
 
  
 
were added. Two rounds of
antigenic stimulation were performed.
For isolation of IFN-
 
 
 
  
 
Th1 cells, 10
 
6
 
/ml T cells cultured un-
der Th1-inducing condition for 7 d were recultured with 100
pM IL-2, 1 
 
 
 
M OVA
 
323–339
 
, plus 10
 
6
 
/ml APC in six-well plates
in a total 3-ml volume. After 8 h, only adherent cells were col-
lected and incubated with the anti-CD45/anti–IFN-
 
  
 
bispecific
antibody capture matrix (Miltenyi Biotec) for 5 min on ice. The
treated cells were transferred to 50-ml conical tubes and cultured
at a concentration of 5 
 
  
 
10
 
4 
 
cells/ml in 20 ml warmed medium
and placed in a 37
 
 
 
C water bath. After 30 min, cells were washed
with cold 0.5% BSA in PBS. Matrix-captured IFN-
 
  
 
was de-
tected with PE anti–IFN-
 
 
 
. IFN-
 
 
 
  
 
cells were isolated by cell
sorting (Elite; Coulter Electronics).
 
Th Clones.
 
Three murine CD4
 
  
 
Th clones designated 9-16
(48), 35-9D (49), and D10.G4.1 (50) were provided by Y. Asano
(Ehime University, Matsuyama, Japan), T. Yoshimoto (Tokyo
Medical University, Tokyo, Japan), and S. Ono (Osaka Univer-
sity, Osaka, Japan), respectively. 9-16 is a KLH-specific, I-A
 
k
 
–
restricted Th1 clone. 35-9D is an OVA-specific, I-A
 
b
 
–restricted
Th1 clone. D10.G4.1 is a conalbumin-specific, I-A
 
k
 
–restricted
Th2 clone.
 
In Vitro Culture.
 
Polarized Th1 and Th2 cells and sorted
IFN-
 
 
 
  
 
cells from Th1 cells were recultured at 10
 
5
 
/0.2 ml/well
with 100 pM IL-2, 1 
 
 
 
M OVA
 
323–339
 
, and 10
 
5
 
/0.2 ml APC in
the presence of various concentrations of IL-18 (0–100 ng/ml).
Th1 clone (9-16) and Th2 clone (D10.4G.1) were cultured at
10
 
5
 
/0.2 ml/well with immobilized anti-CD3 and anti-CD28
(each 5 
 
 
 
g/ml) in the presence of various concentrations of IL-18
(0–100 ng/ml). After 48 h of culture, supernatants were harvested
and tested for IFN-
 
 
 
, IL-4, IL-5, IL-6, IL-9, IL-13, TNF-
 
 
 
,
RANTES, MIP-1
 
 
 
, and GM-CSF contents by ELISA.
 
Flow Cytometry.
 
For intracellular cytokine staining, 10
 
6
 
/ml
polarized Th1 and Th2 cells were restimulated with 100 pM IL-2,
1 
 
 
 
M OVA
 
323–339
 
, and 10
 
6
 
/ml APC with or without 50 ng/ml
IL-18 for 16 h with a pulse of 1 
 
 
 
g/ml Brefeldin A during the fi-
nal 4 h to inhibit cytokine secretion. Such cells were first stained
with PE anti-CD4 and followed by fixation with 4% (wt/vol)
paraformaldehyde in PBS and permeabilization of cell membrane
with ice cold PBS containing 1% FCS plus 0.1% saponin. Result- 
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ant cells were treated with 10 
 
 
 
g/ml anti-Fc
 
 
 
RII/III (24G2) for
30 min and then 10 
 
 
 
g/ml biotinylated goat anti–mouse IL-13
or biotinylated goat anti–mouse IgG (R&D Systems) for 30 min
at 4
 
 
 
C in staining buffer (PBS, 1% FCS). Cells were washed twice
and stained with APC-labeled streptavidin plus FITC rat anti–
mouse IFN-
 
  
 
or isotype-matched control mAb (BD Biosciences)
for 30 min. Samples were analyzed for their proportion of cyto-
plasmic IFN-
 
 
 
  
 
and/or IL-13
 
  
 
cells gated on CD4
 
  
 
T cells by
FACSCalibur™ (BD Biosciences).
For determination of IL-18R
 
  
 
chain expression on Th1 and
Th2 cells, after FcR blocking with anti-Fc
 
 
 
RII/III, cells were
incubated with anti–mouse IL-18R
 
  
 
chain mAb or control rat
IgG1 mAb (R3-34) for 30 min at 4
 
 
 
C, followed by FITC anti–
rat IgG1 Ab and PE anti–mouse CD4 for 30 min at 4
 
 
 
C in stain-
ing buffer. Samples were analyzed on a FACSCalibur™.
 
Transfer of Cells and Administration of OVA Plus IL-18.
 
Prepa-
ration of Th1 or Th2 memory cells in vivo has been described
(51). Equal numbers (10
 
7
 
) of Th1 cells, Th2 cells, or sorted IFN-
 
 
 
  
 
cells were injected i.v. into normal BALB/c mice (10–15 mice
per group). At various times after adoptive transfer, peripheral
blood cells were collected and stained with APC anti-CD4 and
PE-KJ1-26 to ensure that all DO11.10 TCR Tg cells were in-
cluded in the analysis. 30 d after transfer of cells, animals were
daily exposed intranasally to PBS or 1 
 
 
 
g OVA and/or 0.5 
 
 
 
g
IL-18 in 50 
 
 
 
l PBS for 3 d. Control mice were exposed to PBS.
Mice were analyzed at 24 h after the final exposure to Ag. For
the blockade of IL-13 in vivo, 20 
 
 
 
g sIL-13R
 
 
 
2
 
-Fc or 20 
 
 
 
g
control human IgG (Genetics Institute Inc.) was daily adminis-
tered intranasally as the mixed form with OVA and IL-18 for 3 d.
 
Measurement of AHR.
 
We measured AHR to 
 
 
 
-methacho-
line (Mch) inhalation in mice by using Pulmos-I (MIPS) hard-
ware and software. We placed a mouse in a chamber and exposed
it to aerosols of saline (baseline) first and then to increased con-
centrations of Mch (5, 10, 15, and 20 mg/ml). After each 2-min
exposure, we measured enhanced pause, a dimensionless index
that reflects changes in amplitude of pressure wave form and ex-
piratory time (52), for 3 min.
 
Bronchoalveolar Lavage (BAL).
 
BAL was performed with three
aliquots of 0.5 ml PBS per mouse. Total cell counts were per-
formed. Cytospin preparations of BAL fluid (BALF) were stained
Figure 1. IL-18 induced airway
inflammation and AHR in mice re-
ceiving memory Th1 cells. 30 d after
adoptive transfer of OVA-specific
Th1 (e–j) or Th2 cells (k–o) (107
cells per mouse) or none (a–d) into
naive BALB/c mice intravenously,
animals were daily exposed nasally to
PBS alone or 1  g OVA and/or 0.5
 g IL-18 in 50  l PBS for 3 d. The
allergic phenotype was assessed 24 h
after the final exposure to antigen.
Lungs were prepared for histology
by perfusing the animal via the right
ventricle with 10 ml PBS and then
fixed in formalin, cut into 3- m sec-
tions, and stained with hematoxylin
and eosin. a–g, i, and k–n,  50; h, j,
and o,  400. Representative results
of five to seven animals are shown.IL-18–stimulated Th1 Cells Induce Allergic Asthma 538
with Dif-Quik (Baxter Healthcare Corp.) and differentials were
performed based on morphology and staining characteristics.
Histology. Lungs were prepared for histology by perfusing the
animal via the right ventricle with 10 ml PBS and then fixed in
10% buffered formalin, cut into 3- m sections, and stained with
hematoxylin and eosin.
Results
Coadministration of OVA and IL-18 Induces Airway Inflam-
mation and AHR in Mice Receiving OVA-specific Memory Th1
cells. We established Th1 or Th2 cells by two rounds of
7-d stimulation of CD4  T cells obtained from OVA-spe-
cific TCR Tg BALB/c (DO11.10) mice with OVA pep-
tide, IL-12, and anti–IL-4 or with OVA peptide, IL-4, and
anti–IL-12/anti–IFN-  in the presence of APC for 2 wk,
respectively. We then transferred these newly polarized
Th1 or Th2 cells i.v. into normal BALB/c mice (107 per
mouse) and allowed them to adopt a resting memory phe-
notype in vivo (51). 30 d after passive cell transfer, these
recipients were daily treated with intranasal administration
of OVA and/or IL-18 for 3 d. Therefore in this experi-
mental system, we could depict the capacity of the mem-
ory-type Th1 or Th2 cells to induce bronchial asthma in
naive mice. Histopathological analysis of the airways of
each group of mice revealed that Th2 cell–transferred
mice showed a significant increase in the peribronchial and
perivenular infiltration with eosinophils and lymphocytes
when compared with normal mice after nasal exposure to
OVA (Fig. 1, c, m, and o). Furthermore, these mice
showed a dose-dependent AHR to McH challenge (Fig. 2
A). In contrast, mice having received Th1 cells 30 d earlier
showed significant cell infiltration composed mainly of
lymphocytes and neutrophils after OVA administration
(Fig. 1, g and h) but failed to respond to Mch challenge by
AHR (Fig. 2 A). However, when they were nasally ex-
posed to both Ag and IL-18, these mice increased their
pathological changes characterized by massive cell infiltra-
tion (Fig. 1, i and j) and AHR (Fig. 2 A), suggesting that
Ag and IL-18 stimulate Th1 cells to produce cytokines and
chemokines that induce or enhance infiltration with eo-
sinophils, lymphocytes, and neutrophils (Fig. 1, j). In con-
trast, mice that received Th1 or Th2 cells 30 d earlier
showed neither lung inflammation (Fig. 1, e, f, k, and l)
nor AHR (Fig. 2 A) after nasal exposure to PBS or IL-18,
suggesting the contribution of Ag- or Ag plus IL-18–
induced recall responses of memory Th2 or Th1 cells, re-
spectively, to induction of bronchial asthma. Thus, Ag
stimulation of memory Th1 cells induced airway inflam-
mation without AHR, whereas Ag plus IL-18 stimulation
induced both airway inflammation and AHR.
It is important to know the reason why additional ad-
ministration of IL-18 was required to induce bronchial
asthma in Th1 cell–transferred mice. Therefore, we com-
pared the numbers of inflammatory cells infiltrating lung
tissues of Th1 cell–transferred mice after daily exposure to
PBS, Ag, IL-18, or Ag plus IL-18 for 3 d (Fig. 2 B). Analy-
sis of BALF revealed marked elevation of the eosinophil
population in the lungs of Th1 cell–transferred mice after
treatment with OVA plus IL-18, suggesting that Ag and
IL-18 act on Th1 cells to produce soluble mediators that
induce infiltration of eosinophils (Fig. 2 B). We also found
that Ag plus IL-18 administration also induced increases in
the number of lymphocytes, neutrophils, and monocytes
(Fig. 2 B). The degree of the increase in the population of
each type of cells is similar to that observed in BALF of
Th2 cell–transferred mice after treatment with OVA or
OVA plus IL-18 (Fig. 2 B). These results substantiated fur-
ther the result of Fig. 1 that additional IL-18 stimulation
changed quantitatively and qualitatively the constituents of
inflammatory cells in the lungs. Thus, Ag stimulation alone
only induced mild delayed-type hypersensitivity (DTH) in
Figure 2. IL-18 induced AHR and eosinophilia in mice receiving
memory Th1 cells. (A) AHR in response to increased concentrations of
inhaled  -Mch was measured in a whole body plethysmograph. (B) Inflam-
matory cell composition of BALF from mice transferred with OVA-specific
Th1 or Th2 cells and daily treated with intranasal administration of PBS
or OVA and/or IL-18 consecutively for 3 d. Cell differential percentages
were determined by light microscopic evaluation of cytospin preparation.
Data are expressed as absolute numbers of cells. Representative results of
five animals are shown.Sugimoto et al. 539
the lung, whereas Ag plus IL-18 stimulation induced very
severe DTH, leading to induction of bronchial asthma.
IL-18 Stimulates OVA-specific Th1 Cells to Produce IFN- ,
Th2-related Cytokines, GM-CSF, and Chemokines In Vitro.
To understand how Ag and IL-18 induce airway inflamma-
tion and AHR, we next tested the types of cytokines or
chemokines produced by Ag-, IL-2–, and IL-18–stimulated
Th1 cells in vitro. We measured the concentrations of IL-4,
IL-5, IL-6, IL-9, IL-13, TNF- , GM-CSF, RANTES, eo-
taxin, MIP-1 , and IFN-  in the culture supernatant of
Th1 cells because they are reported to be deeply involved
in induction of bronchial asthma (1–7). In particular, the
chemokines RANTES, MIP-1 , and eotaxin are central to
the delivery of eosinophils to the airway (53). Naive CD4 
T cells from OVA-specific TCR Tg mice were primed in
vitro under Th1- or Th2-inducing conditions for two con-
secutive rounds of 7-d stimulation. Upon challenge with
OVA peptide and IL-2, as reported elsewhere, Th2 cells
produced significant amounts of IL-4, IL-5, IL-6, IL-9, and
IL-13 but not IFN- , and Th1 cells produced IFN-  but
not Th2 cytokines (Fig. 3 A). Additional stimulation of Ag
plus IL-2–stimulated Th1 cells with IL-18 dose depen-
dently induced IFN-  (Fig. 3 A; reference 44). Most sur-
prisingly, this treatment simultaneously induced RANTES,
MIP-1 , IL-9, IL-13, TNF-  (not depicted), and GM-
CSF in Th1 cells (Fig. 3 A). Eotaxin was not detectable in
any culture supernatant of Th1 cells. The mechanism un-
derlying this difference in IL-18 responsiveness between
Th1 and Th2 cells is principally explained by preferential
expression of IL-18R  chain on Th1 cells (44). As ex-
pected, Th1 cells express a high level of IL-18R, whereas
Th2 cells express modestly (Fig. 3 B). Furthermore, they si-
multaneously produced a large amount of chemokines (Fig.
3 A). Thus, IL-18R–expressing Th1 cells are target cells for
IL-18 and responded to it not only by increased production
of IFN- , but also by production of some Th2 cytokines
(IL-9 and IL-13), TNF-  (not depicted), GM-CSF, and
chemokines. Because IL-12 plus IL-18 is known to induce
IFN-  production from Th1 cells but inhibit IL-4 and IL-
13 production from Th2 cells in vivo and in vitro (30, 33,
38, 44), it is important to test the effect of IL-12 on the
ability of IL-18 to induce IL-13 from Th1 cells. We found
that IL-12 slightly diminished the production of IL-13 and
GM-CSF from Th1 cells stimulated with IL-18 alone or
Figure 3. IL-18 induced
IFN- , IL-9, IL-13, GM-CSF,
RANTES, and MIP-1  produc-
tion from OVA-specific Th1 cells.
(A) 105/ml naive splenic CD4 
CD62L  T cells from DO11.10
Tg mice were cultured with 100
pM IL-2 plus 1  M OVA323–339
and 106/ml irradiated T cell–
depleted BALB/c splenocytes in
six-well plates in a total 3-ml vol-
ume for 7 d. For differentiation of
Th1 cells, 10 ng/ml IL-12 and
10  g/ml anti–IL-4 were added
to the culture. For the differenti-
ation of Th2 cells, 1,000 U/ml
IL-4, 10  g/ml anti–IL-12p40,
and 10  g/ml anti–IFN-  were
added. Two rounds of antigenic
stimulations under polarizing
conditions were performed. After
priming, cells were washed and
recultured at 105/0.2 ml/well
with 100 pM IL-2, 1  M
OVA323–339, plus 105/0.2 ml irra-
diated T cell–depleted BALB/c
splenocytes in the presence of
various concentrations of IL-18
(0–100 ng/ml). After 48 h of culture, supernatants were harvested and tested
for IFN- , IL-4, IL-5, IL-6, IL-9, IL-13, RANTES, MIP-1 , and GM-
CSF contents by ELISA. Results are geometric means   SEM. (B) Surface
expression of IL-18R  chain by flow cytometry. The percentages shown
represent the proportion of IL-18R  chain  cells among CD4  cells. (C) Polar-
ized Th1 cells were cultured at 105/0.2 ml/well with medium alone or
various combinations of 100 pM IL-2, 20 ng/ml IL-12, and 50 ng/ml IL-18
in the presence of 1  M OVA323–339 plus 105/0.2 ml irradiated T cell–depleted
BALB/c splenocytes. After 48 h of culture, supernatants were harvested and
tested for IFN- , IL-13, and GM-CSF contents by ELISA. Results are geo-
metric means   SEM.IL-18–stimulated Th1 Cells Induce Allergic Asthma 540
IL-18 plus IL-2 in the presence of OVA (Fig. 3 C). More-
over, additional IL-12 stimulation did not affect IL-13 and
GM-CSF production from Th1 cells stimulated with im-
mobilized anti-CD3 plus anti-CD28 antibodies (not de-
picted). Thus, IL-12 is essential for induction of Th1 cells
but not critically involved in induction of cytokine produc-
tion from Th1 cells. As reported elsewhere, Th2 cells failed
to respond to IL-18 by enhanced production of IL-4, al-
though they modestly increased production of IL-5, IL-9,
and IL-13 in response to IL-18 (Fig. 3 A). These results
suggested the possible involvement of cytokines, particu-
larly of IFN- , TNF- , IL-9, IL-13, GM-CSF, and some
chemokines from Th1 cells in induction of both severe air-
way inflammation and AHR.
IL-18 Stimulates Ag-specific Cloned Th1 Cells to Produce IL-
13 and GM-CSF. These results still leave the question of
whether some other contaminated cells, such as NK cells or
NKT cells, might have responded to IL-2 and IL-18 by
production of IL-9, IL-13, and GM-CSF (35, 36). There-
fore, we used cloned Th1 cells (9-16; reference 48) and
Th2 cells (D10.4G.1; reference 50) specific for KLH and
conalbumin, respectively. We stimulated them with immo-
bilized anti-CD3 and anti-CD28 in the presence of various
doses of IL-18. As previously reported, these cloned Th2
cells produced significant amounts of IL-4 and IL-13 but
not IFN- , and cloned Th1 cells produced IFN-   and
GM-CSF but not Th2 cytokines (Fig. 4 A). We found that
like newly established Th1 cells derived from DO11.10, a
large proportion of stable cloned Th1 cells express a high
level of IL-18R  chain and produce GM-CSF and IL-13
dependently of doses of IL-18 used for stimulation (Fig. 4).
In contrast, cloned Th2 cells, even if a substantial fraction
of Th2 cells express IL-18R  chain, did not produce IFN- 
when stimulated with immobilized anti-CD3/anti-CD28
and IL-18 (Fig. 4). We examined another OVA-specific
Th1 clone (35-9D; reference 49). This clone produced sig-
nificant amounts of IFN-  but no IL-4 and IL-13. How-
ever, like 9-16 Th1 clone, 35-9D Th1 clone expressed a
high level of IL-18R  chain (80.0%) and increased IL-13
dependently of doses of IL-18 used for stimulation (not de-
picted). These results strongly indicated that even stable
cloned Th1 cells gained the capacity to produce Th2 cyto-
kines and GM-CSF when they were stimulated with Ag
and IL-18, suggesting the importance of IL-18 in induction
of Th2 cytokines from Th1 cells.
Administration of IL-13 Antagonist Diminishes the Number
of Eosinophils in BALF, but Fails to Abolish Ag plus IL-18–
induced AHR in Th1 Cell–transferred Mice. As IL-13 is re-
ported to participate in airway inflammation and AHR
(16–19), we next blocked the function of this cytokine by
administration of IL-13 antagonist into the mice receiving
Th1 cells (Fig. 5). We administered a soluble IL-13R 2–
human Fc fusion protein (IL-13R-Fc), which selectively
binds to and neutralizes IL-13 but not IL-4 (34, 54), to
these mice and compared them to mice that received con-
trol protein. Although this treatment significantly dimin-
ished the number of eosinophils in BALF (Fig. 5 B), little
effect was seen in AHR upon Mch challenge (Fig. 5 A). In
contrast, as previously reported, administration of IL-13
antagonist diminished both AHR and the number of eosin-
ophils in BALF from Th2-transferred and OVA-stimulated
mice (Fig. 5 B). Therefore, we could exclude the possibil-
ity that IL-13 is responsible for inducing AHR in mice re-
ceiving Th1 cells. Because the number of eosinophils was
markedly diminished by neutralization of IL-13, these in-
flammatory cells were not involved in AHR in this experi-
mental asthma model.
IL-18 Stimulates IFN-   Th1 Cells to Produce IFN- , IL-9,
IL-13, and GM-SCF. Although additional IL-18 stimula-
tion dose dependently induced Ag plus IL-2–stimulated
Th1 cells to produce both IFN-  and IL-13 (Fig. 3 A), we
Figure 4. IL-18 induced IL-13 and GM-CSF production from antigen-
specific Th1 clone. (A) Th1 clone (9-16), KLH-specific, I-Ak–restricted,
and Th2 clone (D10.4G.1), conalbumin-splenic, I-Ak–restricted, were
cultured at 105/0.2 ml/well with immobilized anti-CD3/anti-CD28
(each 5  g/ml) in the presence of various concentrations of IL-18 (0–100
ng/ml). After 48 h of culture, supernatants were harvested and tested for
IFN- , IL-4, GM-CSF, and IL-13 contents by ELISA. Results are geo-
metric means   SEM. (B) Surface expression of IL-18R  chain by flow
cytometry. The percentages shown represent the proportion of IL-18R 
chain  cells among CD4  cells.Sugimoto et al. 541
still needed to exclude the possibility that potentially con-
taminated Th0 cells produce IL-13. To exclude this possi-
bility, we examined the proportions of CD4  T cells pro-
ducing IFN-   and/or IL-13 in Th1 and Th2 cells
stimulated with Ag, IL-2, and IL-18 for 16 h (Fig. 6 A).
Th1 cells showed a significant increase in the proportion of
Th1 cells producing IL-13 alone or both IFN-  and IL-13.
As expected, Th2 cells produced IL-13 but not IFN- , and
responded poorly to additional IL-18 stimulation. These
results strongly indicated that Th1 cells produce both IFN- 
and IL-13 when stimulated with Ag, IL-2, and IL-18.
We finally tested the capacity of highly purified Th1
cells to produce IFN- , GM-CSF, IL-9, and IL-13 in re-
sponse to Ag, IL-2, and IL-18 in vitro (Fig. 6 C). For this
purpose, we purified IFN- –expressing Th1 cells by cap-
turing secreted IFN-  by surface-bound anti–IFN-  anti-
body. As shown in Fig. 6 B, 6.3% of Th1 cells express
IFN-  on their cell surfaces when Th1 cells stimulated
with OVA peptide in the presence of APC for 8 h were
examined by the affinity matrix technology, which allows
detection of IFN-  production by living cells. We then
positively purified IFN- –producing living IFN-   CD4 
Th1 cells (98.7%) by a fluorescence cell sorter. Culturing
of sorted IFN-   Th1 cells with OVA, IL-2, and IL-18 in
the presence of APC led to an increase in IL-9, IL-13,
IFN- , and GM-CSF but not IL-4 production (Fig. 6 C).
Thus, we could formally conclude that Ag, IL-2, and IL-
18 can stimulate Th1 cells to produce IFN- , GM-CSF,
IL-9, and IL-13. To further clarify the pathological rele-
vance of Th1 cells, we transferred FACS®-sorted OVA-
specific IFN-   Th1 cells into normal BALB/c mice and
allowed them to adopt a resting memory phenotype. 30 d
after cell transfer, these mice were nasally exposed to OVA
plus IL-18 for 3 d. These animals developed peribronchial
and perivenular infiltration with eosinophils and lympho-
cytes when examined by histopathologic analysis (Fig. 6
D) and showed a striking increase in AHR upon Mch
challenge (unpublished data). Taken together, these results
indicated that living IFN-   Th1 cells, when stimulated
with Ag and IL-18 in vivo, induce airway inflammation
and bronchial asthma in unsensitized host mice. However,
blockage of IL-13 again failed to inhibit airway inflamma-
tion and AHR, even though this treatment depleted eo-
sinophils in the lung tissue (not depicted), suggesting the
contribution of Ag plus IL-18–stimulated Th1 cells to in-
duction of bronchial asthma.
Discussion
Th1-dominant immune responses have generally been
considered pathologic in autoimmune disease but protec-
tive against Th2-related diseases (asthma, atopy, etc.; 21).
We demonstrated that intranasal administration of Ag in-
duced airway inflammation without AHR in mice receiv-
ing memory-type Th1 cells. Because Th1 cells induce
DTH, we suspected that this Ag-induced DTH is a physio-
logical response and is not responsible for inducing patho-
logical manifestations such as AHR. In contrast, intranasal
Figure 5. Effect of the IL-13 blockage on IL-18
induced  AHR and eosinophilia in mice receiving
memory Th1 cells. 30 d after adoptive transfer of
OVA-specific Th1 or Th2 cells (107 cells per mouse)
into naive BALB/c mice intravenously, animals were
daily exposed intranasally to PBS, 1  g OVA alone, or
OVA plus 0.5  g IL-18 in 50  l PBS for 3 d. For the
blockade of IL-13 in vivo, 20  g sIL-13R 2-Fc or 20
 g control human IgG were daily administered intra-
nasally as the mixed form with OVA and IL-18 for 3 d.
24 h after the final exposure to antigen, AHR in response
to increasing concentrations of inhaled  -Mch (A) and
inflammatory cell composition of BALF (B) were exam-
ined as described in Fig. 2. Representative results of
four animals are shown.IL-18–stimulated Th1 Cells Induce Allergic Asthma 542
administration of Ag and IL-18 induced severe airway in-
flammation associated with AHR. Thus, Th1 cells become
very harmful cells that induce pathological DTH when
they are stimulated with Ag and IL-18.
Human bronchial asthma is characterized by airway hy-
persensitivity, eosinophilic airway inflammation, airway re-
modeling, mucus hypersecretion, and a high level of IgE
(1–4). These findings have been traditionally explained by
excited state of Th2 cells (5–7). Indeed, inactivation of
GATA-3 significantly diminishes airway inflammation and
hypersensitivity (55–57). As IFN-   antagonizes Th2 re-
sponse, Th1 cells have been regarded to be protective
against asthma (21–23). However, recent studies revealed
the contribution of Th1 cells to induction of bronchial
asthma (1, 24–29). Cotransfer of allergen-specific Th1 and
Th2 cells induce asthma (25). Furthermore, allergen-spe-
cific Th1 cells fail to counterbalance Th2 cell–mediated
airway hypersensitivity (24). Several studies suggested that a
combination of Th1 and Th2 cells instead of mutual inhi-
bition (26, 27) augment each activity to induce bronchial
asthma, suggesting the importance of both Th1 and Th2
cytokines. Indeed, IFN-  and IL-13 induce most severe
bronchial asthma (28). Furthermore, a recent study suggests
another possibility that Th1 cells induce airway hypersensi-
tivity by recruitment and activation of neutrophils (29).
Therefore, Th1 cells become pathological cells under some
conditions. Thus, bronchial asthma might be categorized
into three types; Th1 cell–induced asthma, Th2 cell–
induced asthma, and Th1/Th2 mixed cell–induced asthma.
Th2 cell–induced bronchial asthma is inhibited by neu-
tralization of IL-13 (16, 17). Th1 cell–induced bronchial
asthma is controlled by inhibition of the function of che-
mokines (29). It is well-known evidence that Th1 cells but
not Th2 cells express IL-18R   (44). We previously
showed that IL-18 in collaboration with IL-12 strongly in-
duces Ag or anti-CD3–activated Th1 cells to produce
IFN- , suggesting that Th1 cells are major target cells for
IL-18 (44). Therefore, it is important to compare the re-
sponsiveness of Th1 cell– or Th2 cell–administered mice to
the exposure of Ag and IL-18. We established Th1- or
Th2-type memory T cells. We revealed that administration
of memory-type Th1 or Th2 cells induced bronchial
asthma in an entirely different manner (Figs. 1 and 2). Th1
cell–administered mice require nasal exposure to both Ag
and IL-18 to develop bronchial asthma, whereas Th2 cell–
administered mice only required Ag. An in vitro study re-
Figure 6. IL-18 induced IL-9,
IL-13, and GM-CSF production
from IFN-   Th1 cells. (A) 106/
ml polarized Th1 and Th2 cells,
as described in Fig. 3, were restim-
ulated with 100 pM IL-2, 1  M
OVA323–339, and 106/ml APC
with or without 50 ng/ml IL-18
for 16 h. Intracellular IL-13 and
IFN-   staining was performed
and analyzed as described in
Materials and Methods. Numbers
represent the percentage of IFN-
   and/or IL-13  cells gated on
CD4  T cells. (B) 106/ml polar-
ized Th1 cells were challenged
with 106/ml OVA peptide and
APC in six-well plates in a total
3-ml volume. After 8 h, cells
were collected and incubated
with the anti-CD45/anti–IFN- 
bispecific antibody capture matrix
for 5 min on ice. The resultant
cells were incubated and then
washed as described in Materials
and Methods. Matrix-captured
IFN-   was detected with PE
anti–IFN- . This IFN-   CD4 
T cell population was then isolated
by cell sorting. Numbers repre-
sent the percentage of IFN-  
gated on CD4  T cells. (C) IFN-
   cells were washed and recul-
tured at 105/0.2 ml/well with
100 pM IL-2, 1  M OVA323–339,
plus 105/0.2 irradiated APC in
the presence of various concen-
trations of IL-18 (0–100 ng/ml). After 48 h of culture, supernatants were harvested and tested for IFN- , IL-4, IL-9, IL-13, and GM-CSF contents by
ELISA. Results are geometric means   SEM. (D) 20 d after adoptive transfer of OVA-specific IFN-   cells (107 cells per mouse) into naive BALB/c
mice intravenously, animals were daily exposed intranasally to PBS alone or 1  g OVA plus 0.5  g IL-18 in 50  l PBS for 3 d. 24 h after the final
exposure to antigen, lungs were stained with hematoxylin and eosin. a and b,  40; c,  160.Sugimoto et al. 543
vealed that Th1 cells produce IFN- , GM-CSF, TNF- ,
IL-9, IL-13, RANTES, and MIP-1   upon stimulation
with Ag, IL-2, and IL-18 (Fig. 3 A). Thus, Ag plus IL-18–
stimulated Th1 cells produced a similar spectrum of cyto-
kines and chemokines to that produced by activated mast
cells. Although Th1 cell–administered mice developed se-
vere AHR, we could not detect Ag-specific IgE in their
sera (not depicted), suggesting the important role of ad-
ministered memory-type Th1 cells in the induction of
AHR in an IgE-independent manner.
Here we could induce unique bronchial asthma by acti-
vation of Th1 cells with Ag and IL-18 to produce IFN- ,
GM-CSF, TNF- , IL-9, IL-13, RANTES, and MIP-1  in
normal BALB/c mice. We could also induce Th2-type
asthma by the transfer of memory-type Th2 cells (Figs. 1
and 2). As previously reported (16, 17), we could show that
neutralization of IL-13 inhibits this Th2 cell–induced AHR
(Fig. 5), suggesting contribution of IL-13 to Th2-induced
bronchial asthma (Fig. 5). In contrast, neutralization of IL-
13 did not affect Th1 cell–induced AHR, although this
treatment strongly diminished infiltration with eosinophils
(Fig. 5). As Th1 cells produce IFN- , GM-CSF, TNF- ,
IL-9, IL-13, and chemokines when they are stimulated
with Ag, IL-2, and IL-18 in vitro, it might be important to
point out the possibility that administration of memory-
type Th1 cells could mimic the mixed asthma responses
that are attainable by activation of both Th1 and Th2 cells.
Eosinophils have been implicated as primary effecter cells in
asthma and asthmatic AHR (58). Neutralization of IL-13
markedly diminished the number of eosinophils in the
lungs of mice that were first transferred with memory-type
Th1 and lately exposed to Ag and IL-18. Nevertheless,
these mice developed a comparable level of AHR to that of
control mice, suggesting the contribution of cytokines
other than IL-13 to the development of AHR in Th1 cell–
transferred mice. Thus, Ag plus IL-18–stimulated Th1 cells
induce bronchial asthma independently of IL-13.
It is intriguing to speculate that IL-13 production from
Th2 cells may induce accumulation and activation of eosin-
ophils to produce eosinophil-specific basic proteins (major
basic protein, eosinophil cationic protein, and eosinophil
peroxidase), eosinophil-derived neurotoxins, and lipid me-
diators to induce the pathological process of bronchial
asthma. Because Ag plus IL-18–stimulated Th1 cells pro-
duce both IL-13 and IFN-  (Fig. 6 A), IFN-  may partly
inhibit the action of IL-13 to induce AHR. However,
aside from this action, IFN-  may directly activate accu-
mulated neutrophils to produce chemical mediators and re-
active oxygen intermediates, which in combination may
strongly induce bronchial asthma. If these assumptions are
right, we can understand the reason why simple depletion
of eosinophils failed to attenuate bronchial asthma in hu-
man studies (59). Depletion of neutrophils may also be
needed to attenuate bronchial asthma. Indeed, neutraliza-
tion of some other factors including chemokines, particu-
larly CXC chemokines, sometimes attenuates the AHR in
Th1 cell–induced asthma (29). Indeed, we could detect sig-
nificant amounts of RANTES and MIP-1  in BALF ob-
tained from the mice that were adoptively transferred with
Th1 cells and lately challenged with OVA and IL-18 (not
depicted), even though BALF was diluted with washing
fluid. In contrast, neither RANTES nor MIP-1  was de-
tected in BALF from mice challenged with OVA alone
(not depicted). We need further study to substantiate this
hypothesis that IFN- –stimulated neutrophils contribute to
induction of bronchial asthma.
In addition to IFN-  and IL-13 (Fig. 6 A), Ag plus IL-
18–stimulated Th1 cells produced a variety of cytokines in-
cluding IL-9, GM-CSF, RANTES, and MIP-1 . Mast
cells, when activated with allergen that cross-links IgE mol-
ecules on the cell surface, also produce various types of cy-
tokines, chemokines, and chemical mediators (1, 60). How-
ever, we recently found that IL-18 directly stimulates mast
cells and basophils to produce Th2 cytokines and chemical
mediators (33). However, as simple administration of IL-18
failed to induce airway inflammation (Fig. 1) and bronchial
asthma in normal mice, we suspected the importance of ac-
tivation of Th1 cells with Ag and IL-18 instead of IL-18–
dependent activation of mast cells to induce asthma in the
naive animals that are equipped with memory-type Th1
cells but lack both Ag-specific IgE and activated mast cells.
We found that like activated mast cells (1, 60), Ag plus IL-
18–stimulated Th1 cells produce Th1 cytokines, Th2 cyto-
kines, and chemokines. As IL-18 is abundantly stored in the
epithelial cells of various organs (39–42), we could assume
that some types of infectious agents induce IL-18 produc-
tion from bronchial epithelial cells. Ag from the infectious
agent and IL-18 from epithelial cells then stimulate mem-
ory-type Th1 cells, which were induced by previous infec-
tion, to produce cytokines including IFN- , IL-9, IL-13,
GM-CSF, TNF- , RANTES, and MIP-1 . Thus, Th1
cells may play a relevant role in induction of bronchial
asthma under some infectious conditions.
Here we demonstrated that Th1 cells are critically in-
volved in the induction of airway hypersensitivity and histo-
pathological changes. Th1 cells have the striking capacity to
produce IFN- , IL-9, IL-13, GM-CSF, RANTES, and
MIP-1  when they are stimulated with Ag, IL-2, and IL-18
in vitro (Figs. 3 A and 6 C). Moreover, passive transfer of
Th1 cells causes normal mice to develop severe airway in-
flammation and AHR when they are nasally exposed to Ag
and IL-18 (Figs. 1 and 2). Thus, memory-type Th1 cells be-
come pathological cells when they are stimulated with Ag
and IL-18 in vivo. Although we could depict the asthma-
associated cytokines in the products of Ag-, IL-2–, and IL-18-
stimulated Th1 cells, we still need to identify the definitive
causative effecter cells or factors in this experimental bron-
chial asthma model. However, most importantly, we could
reveal that IL-18 is an upstream cytokine of IFN- , IL-9,
IL-13, GM-CSF, TNF- , RANTES, and MIP-1 , provid-
ing a potential therapeutic target molecule for the establish-
ment of the treatment for allergic disorders.
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